NCT03247673View on ClinicalTrials.gov

To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin

PHASE1CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

August 7, 2017

Primary Completion Date

December 22, 2017

Study Completion Date

January 17, 2018

Conditions
Healthy
Interventions
DRUG

CT-P16

CT-P16 is a biosimilar product for Avastin

DRUG

EU-approved Avastin

EU-approved Avastin

DRUG

US-licensed Avastin

US-licensed Avastin

Trial Locations (3)

Unknown

Inje University Busan Paik Hospital, Busan

Inha University Hospital, Incheon

Seoul St.Mary's hospital, Seoul

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT03247673 - To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin | Biotech Hunter | Biotech Hunter